Skip to content

Dyadic Management Intervention in Older People With Co-occurring Cognitive Impairment and Diabetes as a Supplementary Approach to Chronic Diseases Self-Management Program

Dyadic Management Intervention in Older People With Co-occurring Cognitive Impairment and Diabetes as a Supplementary Approach to Chronic Diseases Self-Management Program: A Hybrid Effectiveness-implementation Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07496359
Enrollment
309
Registered
2026-03-27
Start date
2026-04-01
Completion date
2027-12-01
Last updated
2026-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Caregiver, Choroid Disease, Diabetes, Mild Cognitive Impairment, Older Adults, Self-management

Brief summary

The goal of this study is to evaluate the effectiveness and implementation of a dyadic management of the Chronic Disease Self-Management Program (CDSMP) for older adults with co-occurring cognitive impairment and diabetes with the involvement of caregivers. The main questions it aims to answer are: * Does the intervention improve diabetes self-management and cognitive function in older adults? * How is the implementation of the intervention in real-world settings? Participants will: * Attend weekly CDSMP session over a 6-week period (2.5-hour per session). * Provide feedback on their experience with the intervention through interviews and surveys.

Interventions

BEHAVIORALCDSMP + caregiver support

The CDSMP is an evidence-based program consisting of 2.5-hour sessions held weekly over a six-week period, delivered by two trained leaders per session in person.

BEHAVIORALUsual Care

Usual care (diabetes education, glucose monitoring and medical consultation)

Sponsors

The Hong Kong Polytechnic University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Individuals with DM aged \>= 55 years old; * Recent glycosylated haemoglobin (HbA1c) level of 6.5% or above without change in diabetes medication within the last 3 months based on centre's records; * Subjective cognitive decline (using SCDQ21) (separately reported by the patient and/or caregiver) and confirmed by MOCA (Chinese version) screened by the research nurses; * Subjects with nominated primary caregivers will be recruited in the intervention group; * For caregivers: they will be considered in the project if they have been the primary caregiver for the person for at least 1 year and are providing or involved in the patient's care on a daily basis.

Exclusion criteria

* Medical diagnoses of dementia; * Those who have terminal illness; * For caregivers: those who are temporary caregivers and have only provided/involved in care for less than a year.

Design outcomes

Primary

MeasureTime frameDescription
Self-Care of Diabetes IndexFrom enrollment to 6 months after the intervention beginsSelf-Care of Diabetes Index (SCODI) is a scale, scoring from 0 to 100, where higher scores indicate better self-care for diabetes.

Secondary

MeasureTime frameDescription
Glycated hemoglobin (HbA1c)From enrollment to 6 months after the intervention beginsGlycated hemoglobin (HbA1c) measures average blood sugar levels over the past 2-3 months, acting as a crucial diagnostic and management tool for diabetes. A level below 7% is recommended for patients with diabetes.
Subjective Cognitive Decline Questionnaire 21From enrollment to 6 months after the intervention beginsSubjective Cognitive Decline Questionnaire 21 (SCD-Q21) is a reliable, validated 21-item tool designed to detect self-reported cognitive changes, helping distinguish Mild Cognitive Impairment (MCI) from healthy people. The score is from 0 to 21, with a higher score corresponding to a greater likelihood of MCI.
Montreal Cognitive AssessmentFrom enrollment to 6 months after the intervention beginsMontreal Cognitive Assessment (MoCA) is a widely used screening scale designed to detect mild cognitive impairment, with scores from 0 to a maximum of 30 points. A higher score on MoCA indicates better cognitive function and less impairment.
Caregiver Contribution to Self-Care of Diabetes InventoryFrom enrollment to 6 months after the intervention beginsCaregiver Contribution to Self-Care of Diabetes Inventory (CC-SCODI) is a validated scale measuring caregiver efforts in diabetes maintenance, monitoring, and management. The score is from 0 to 100 points, with a higher score indicating higher caregiver involvement.
Caregiver Burden InventoryFrom enrollment to 6 months after the intervention beginsCaregiver Burden Inventory (CBI) is a scale measuring multidimensional caregiver burden. Score is from 0 to 96 points, with a higher score indicating higher perceived caregiver burden.
Implementation Outcome: Acceptability of Intervention MeasureFrom 3 months after the intervention begins to 6 months after the intervention beginsAcceptability of Intervention Measure (AIM) is a questionnaire assesses how acceptable the intervention is perceived to be by the participants. The total score ranges from 4 to 20, with higher scores indicating greater acceptability of the intervention. Additionally, qualitative interviews with patients and relevant stakeholders are conducted to further evaluate this outcome.
Implementation Outcome: Intervention Appropriateness MeasureFrom 3 months after the intervention begins to 6 months after the intervention beginsIntervention Appropriateness Measure (IAM) is a questionnaire evaluates how suitable or relevant the intervention is for the intended purpose or context. The total score ranges from 4 to 20, with higher scores indicating the intervention is perceived as more appropriate. Additionally, qualitative interviews with patients and relevant stakeholders are conducted to further evaluate this outcome.
Implementation Outcome: Feasibility of Intervention MeasureFrom 3 months after the intervention begins to 6 months after the intervention beginsImplementation Outcome: Feasibility of Intervention Measure (FIM) is a questionnaire examines how practical and implementable the intervention is in real-world settings. The total score ranges from 4 to 20, with higher scores indicating greater feasibility of implementing the intervention. Additionally, qualitative interviews with patients and relevant stakeholders are conducted to further evaluate this outcome.
Implementation Outcome: AdoptionFrom 3 months after the intervention begins to 6 months after the intervention beginsThis Adoption questionnaire is derived from the Measuring the Use of the RE-AIM Model Dimension Items Checklist and is designed to assess the adoption of an intervention at both the setting and staff levels. It evaluates factors such as participation rates, reasons for exclusion, and characteristics of participating versus non-participating settings and staff. The measure does not use a specific scoring system; instead, it relies on qualitative and descriptive insights to explore adoption. Additionally, qualitative interviews with patients and relevant stakeholders are conducted to further evaluate this outcome.
Implementation Outcome: FidelityFrom 3 months after the intervention begins to 6 months after the intervention beginsThis Fidelity questionnaire is derived from the Fidelity Checklist for Chronic Disease Self-Management Education Programs and is designed to evaluate the consistency and quality of program implementation. It uses a performance checklist to ensure that the intervention is delivered as intended. The measure does not use a specific scoring system; instead, it relies on qualitative and descriptive insights to explore adoption. If more items on the Fidelity Checklist are met, it indicates better fidelity to the program's design. Additionally, qualitative interviews with patients and relevant stakeholders are conducted to further evaluate this outcome.
Implementation Outcome: CostFrom 3 months after the intervention begins to 6 months after the intervention beginsThis cost outcome focuses on evaluating the economic aspects of the intervention by measuring health-related quality of life using the EQ-5D-5L questionnaire (EuroQol 5-Dimension 5-Level questionnaire), collecting expenditures associated with delivering the intervention (e.g., material costs, staff training, and technical support), and assessing patients' health utilization costs, such as medical expenses, follow-up time, and related financial costs (e.g., transportation). It also considers indirect costs, such as income loss for patients or caregivers, long-term healthcare savings from improved outcomes, and time costs for participants and staff. The collected data will support a cost-effectiveness analysis, providing a comprehensive evaluation of the intervention's value relative to its costs. Additionally, qualitative interviews with patients and relevant stakeholders are conducted to further evaluate this outcome.
Implementation Outcome: PenetrationFrom 3 months after the intervention begins to 6 months after the intervention beginsThis Penetration questionnaire is derived from the RE-AIM Model Dimension Items Checklist and is designed to evaluate how representative the enrolled patients are of the target population by counting and comparing the number of patients with co-occurring diabetes and MCI who are eligible, invited, excluded, and enrolled to receive CDSMP within participating organizations. Comparisons will be made to non-participants based on key demographic data, including age, diabetes type, MOCA scores and duration, and the number of follow-up attendances. Additionally, qualitative interviews with patients and relevant stakeholders are conducted to further evaluate this outcome.
Implementation Outcome: SustainabilityFrom 3 months after the intervention begins to 6 months after the intervention beginsThis Sustainability questionnaire is derived from the RE-AIM Model Dimension Items Checklist and is designed to assess the sustainability of an intervention over time. It includes three key components: Maintenance, which evaluates the long-term impact and continuation of the intervention; Individual Level, which focuses on the persistence of individual behavior changes and health outcomes (e.g., maintaining improvements in quality of life or clinical outcomes at 6 months or more post-intervention); and Setting Level, which examines whether the intervention is institutionalized within the organization, including alignment with the organization's mission, resource allocation, and adaptation for long-term implementation. The measure relies on qualitative and descriptive insights rather than a specific scoring system. Additionally, qualitative interviews with patients and relevant stakeholders are conducted to further evaluate this outcome.

Countries

Hong Kong

Contacts

CONTACTJed Montayre
jed-ray.montayre@polyu.edu.hk85227666393

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 18, 2026